Therefore, BIA represents a valuable tool for monitoring the effects of dietary strategies and therapies with GLP-1 receptor agonists, supporting personalised nutritional and therapeutic decision-making over time
Jump to 10:10 for this segment
Recent studies relating to patients with coronary artery disease have highlighted marked increases in populations of some bacteria in the gut, while the number of beneficial bacteria like Bacteroidetes and Lactobacillus are reduced (Verhaar et al., 2020)
To mitigate any potential negative effects on methylation, additional interventions can support the methyl cycle while using folinic acid therapy: Improving SAH (S-adenosylhomocysteine) levels by reducing homocysteine through methyl donors like betaine (TMG), vitamin B6 (P5P), and methylcobalamin (B12)
Low-concentration paclitaxel (36 nM) is reported to interfere with glutaminolysis, a process that is essential for ferroptosis
Call to Action: Please schedule a visit with our providers today to review all your options